Clinical Trials Logo

Sepsis, Severe clinical trials

View clinical trials related to Sepsis, Severe.

Filter by:

NCT ID: NCT03685214 Recruiting - Sepsis Clinical Trials

Comparison of Balanced Crystalloids and Normal Saline in Septic Patients

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

In this prospective randomized controlled trial, investigators attempt to study the effects of acetated Ringer's solution on the prognosis and renal function of patients with sepsis in intensive care unit compared with normal saline, and provide evidence for current fluid resuscitation strategies for sepsis.

NCT ID: NCT03422159 Completed - Septic Shock Clinical Trials

Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis.

ORANGES
Start date: February 5, 2018
Phase: Phase 2
Study type: Interventional

This study has been created to compare the addition of intravenous (IV) vitamin C, thiamine, and hydrocortisone to the usual standard of care of sepsis and septic shock. Sepsis is a possibly life-threatening condition in which a patient may have organ dysfunction due to an infection. Septic shock is defined as low blood pressure and organ dysfunction that do not improve after administering IV fluids. Standard of care for sepsis and septic shock include early administration of IV antibiotics, IV fluids, and vasopressors if need be to provide oxygen to vital organs. A large amount of experimental data has shown that vitamin C and corticosteroids decrease the release of inflammatory substances which may lead to organ failure seen in sepsis. Vitamin C and corticosteroids also improve blood flow to vital organs and increase the body's ability to respond well to vasopressor medications used in septic shock. Low blood levels of both thiamine and vitamin C are common in sepsis. The study will be placebo controlled, meaning one group will receive vitamin C, thiamine, and hydrocortisone, and the other will receive an inactive substance ("placebo"). The goal of the study is to compare the effects of receiving vitamin C, thiamine, and hydrocortisone (along with the standard sepsis care) versus placebo and standard sepsis care.

NCT ID: NCT03405870 Recruiting - Septic Shock Clinical Trials

LIPIDS-P Trial Phase I/II

LIPIDS-P
Start date: August 17, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Briefly, this pilot clinical trial will evaluate preliminary safety and efficacy of the study drug (Smoflipid) at elevating cholesterol levels (primary outcome) in patients with sepsis and moderate organ dysfunction and will also evaluate measures of organ dysfunction, mortality, and biological activity (secondary outcomes).

NCT ID: NCT03367026 Not yet recruiting - Sepsis, Severe Clinical Trials

Reducing Elevated Heart Rate in Patients With Severe Sepsis by Ivabradine

REHSI
Start date: January 1, 2018
Phase: N/A
Study type: Interventional

REHSI is a prospective, multi-center, open label, randomized, controlled two arms, to evaluate the ability of ivabradine to reduce an elevated heart rate in septic shock patients. The primary end point is the reduction of heart rate within 24 hours. This trial will randomize 70 patients (men and women, aged ≥ 18 years) with newly diagnosed Septic Shock (despite adequate fluid resuscitation, were still requiring high-dose norepinephrine (NE) to maintain a mean arterial pressure (MAP) ≥65 mmHg , and had a tachycardia >100 beats per minute (bpm). Treatment period will last 4 days. All patients will be followed for up to six months.

NCT ID: NCT03249597 Completed - Sepsis Clinical Trials

Predict Sepsis; the Predictive Value of Bedside Measures in the Ambulance

Start date: April 3, 2017
Phase:
Study type: Observational

Sepsis is a condition with a high mortality. Septic patients are frequently difficult to identify because of their non-specific presentations. There is also a low sensitivity of clinical judgment among health care personnel, and of existing screening tools, which are in turn typically based on vital parameters. Despite prior research, no unique sepsis biomarker has been identified so far. There is a need for new strategies to identify sepsis which do not rely on vital parameters and traditional laboratory blood tests alone. The hypothesis of the investigators is that a combination of clinical variables measurable in the ambulance can be used to predict sepsis. The aim of the current study is to determine the predictive value of keywords related to symptom presentation, vital parameters and point-of-care (POC) blood tests, alone and in combination, with respect to the outcome sepsis. The study is performed in the Stockholm ambulance setting from April 2017. A total of 956 adult non-trauma patients will be included.

NCT ID: NCT03244293 Recruiting - Sepsis, Severe Clinical Trials

Bispectral Index (BIS) for Classification of Procalcitonin (PCT) Sepsis Grades in Critically Ill Patients With Sepsis

BIS6
Start date: January 1, 2014
Phase:
Study type: Observational

To evaluate the discriminative power of BIS monitoring to classify the degree of mental state associated with the PCT graded sepsis cascade, and to assess its utility for monitoring the improvement or deterioration of sepsis.

NCT ID: NCT03044223 Recruiting - Sepsis Clinical Trials

Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis

MIPSA
Start date: August 2014
Phase:
Study type: Observational

The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in critically ill patients with PSA-sepsis, and whether the severity of sepsis and outcome is associated with distinct monocyte phenotype and function.

NCT ID: NCT02765191 Completed - COVID-19 Clinical Trials

MR-Evaluation of Renal Function In Septic Patients

MERSEP
Start date: December 7, 2016
Phase: N/A
Study type: Interventional

A study of renal blood flow and renal oxygenation measured by magnetic resonance after a standardized fluid challenge in critically ill, resuscitated, patients with sepsis due to COVID-19 or other agents.